EMBC
Embecta Corp. NASDAQ$9.25
Pre-mkt
$5.15
-44.32%
Mkt Cap $547.8M
52w Low $8.47
11.0% of range
52w High $15.55
50d MA $9.27
200d MA $11.89
P/E (TTM)
5.6x
EV/EBITDA
6.9x
P/B
—
Debt/Equity
-2.2x
ROE
-22.8%
P/FCF
4.5x
RSI (14)
—
ATR (14)
—
Beta
1.10
50d MA
$9.27
200d MA
$11.89
Avg Volume
872.6K
About
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and inte…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2026 | BMO | 0.67 | 0.71 | +6.0% | 10.47 | +0.5% | +3.8% | -1.6% | -1.7% | -3.9% | -4.5% | — |
| Nov 25, 2025 | BMO | 0.70 | 0.50 | -28.6% | 13.58 | -1.6% | -7.4% | -6.0% | -9.8% | -9.4% | -12.0% | — |
| Aug 8, 2025 | BMO | 0.46 | 1.12 | +146.2% | 12.28 | +1.0% | +3.7% | +8.5% | +13.5% | +12.9% | +11.5% | — |
| May 9, 2025 | BMO | 0.66 | 0.70 | +6.1% | 11.97 | +4.1% | +3.7% | +4.4% | -3.2% | -2.6% | +0.4% | — |
| Feb 6, 2025 | BMO | 0.45 | 0.65 | +44.4% | 17.73 | -0.1% | -1.7% | -1.3% | -1.3% | -6.3% | -8.9% | — |
| Nov 26, 2024 | BMO | 0.36 | 0.45 | +25.0% | 18.70 | +4.7% | +10.1% | +11.4% | +10.3% | +9.3% | +9.6% | — |
| Aug 9, 2024 | BMO | 0.48 | 0.74 | +54.2% | 15.39 | -0.3% | -4.2% | -3.7% | -4.2% | -5.3% | -7.7% | — |
| May 9, 2024 | BMO | 0.43 | 0.67 | +55.8% | 14.16 | +2.8% | +0.6% | +0.1% | +3.1% | -2.9% | +0.3% | — |
| Feb 9, 2024 | BMO | 0.45 | 0.61 | +35.6% | 16.26 | -0.1% | -7.9% | -12.4% | -10.6% | -9.1% | -10.9% | — |
| Nov 21, 2023 | BMO | 0.42 | 0.59 | +40.5% | 17.06 | +2.4% | +3.3% | +2.5% | +1.9% | +2.6% | +6.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 | Mizuho | Maintains | Neutral → Neutral | — | $8.85 | $8.81 | -0.5% | +4.6% | +6.9% | +8.6% | +7.5% | +10.5% |
| Feb 6 | BTIG | Maintains | Buy → Buy | — | $10.47 | $10.52 | +0.5% | +3.8% | -1.6% | -1.7% | -3.9% | -4.5% |
| Sep 5 | BTIG | Maintains | Buy → Buy | — | $14.49 | $14.48 | -0.1% | +3.2% | +1.1% | +5.1% | +3.3% | +5.7% |
| Jul 16 | Mizuho | Maintains | Neutral → Neutral | — | $9.58 | $9.68 | +1.0% | +1.8% | +2.8% | +2.1% | +7.4% | +11.6% |
| May 23 | Mizuho | Maintains | Neutral → Neutral | — | $10.51 | $10.40 | -1.0% | +2.0% | +7.1% | +0.4% | -0.5% | +0.2% |
| Nov 27 | BTIG | Upgrade | Neutral → Buy | — | $18.70 | $19.57 | +4.7% | +10.1% | +11.4% | +10.3% | +9.3% | +9.6% |
| Jul 15 | Morgan Stanley | Maintains | Underweight → Underweight | — | $13.17 | $12.90 | -2.1% | -2.5% | +0.2% | +3.3% | +1.4% | +0.0% |
| May 10 | Morgan Stanley | Maintains | Underweight → Underweight | — | $14.16 | $14.56 | +2.8% | +0.6% | +0.1% | +3.1% | -2.9% | +0.3% |
| Nov 22 | Morgan Stanley | Maintains | Underweight → Underweight | — | $17.06 | $17.47 | +2.4% | +3.3% | +2.5% | +1.9% | +2.6% | +6.1% |
| Oct 18 | Morgan Stanley | Maintains | Underweight → Underweight | — | $15.59 | $15.08 | -3.3% | -1.2% | -1.7% | -0.6% | -0.5% | +5.3% |
Recent Filings
8-K · 2.02
!! High
Embecta Corp. -- 8-K 2.02: Earnings Results
Embecta Corp. reported first-quarter 2026 earnings results, providing investors with updated financial performance metrics for the quarter ending March 31, 2026.
May 5
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
This standard SEC boilerplate about furnishing documents upon request carries no material implications for EMBC's stock, as it merely describes routine regulatory compliance procedures rather than substantive business developments.
Mar 20
8-K
Embecta Corp. -- 8-K Filing
Embecta Corp. shareholders approved executive compensation packages for named officers through say-on-pay voting, indicating investor support for management's remuneration structure.
Feb 13
8-K
Embecta Corp. -- 8-K Filing
Embecta is prioritizing strengthening its injection product market leadership while expanding its portfolio and reducing debt to improve financial flexibility.
Feb 5
Data updated apr 25, 2026 7:03am
· Source: massive.com